Innovent Bio to build global biopharmaceutical hub in Hongqiao

Innovent Bio builds a global R&D center in Shanghai's Hongqiao International Central Business District. [Photo/WeChat ID: hongqiaoshangwuqu]

As Innovent Bio's global R&D center in Shanghai's Hongqiao International Central Business District nears completion, the company is set to enhance its position in the biopharmaceutical industry. Founded in 2011, Innovent focuses on creating innovative drugs in oncology, autoimmune diseases, metabolism, and ophthalmology.

According to Zhao Lei, general manager of Innovent's Shanghai branch, choosing to settle in Hongqiao was strategic. The location offers excellent transportation links, fostering client visits and employee travel. Additionally, Hongqiao's focus on biopharmaceutical R&D headquarters promotes industry synergy and innovation. The district's comprehensive support in project procedures and talent rewards further influenced the decision.

Zhao Lei, general manager of Innovent Bio's Shanghai branch. [Photo/WeChat ID: hongqiaoshangwuqu]

The new R&D center will specialize in global drug research and development, aiming to become a leading hub by integrating scientific research and technological application. Innovent's mission of providing affordable, high-quality biopharmaceuticals is evident in its patient assistance projects, which have benefited over 170,000 patients.

Innovent, with 10 approved products already in the market and several others in development, expects to gain from Hongqiao's policy guidance, enhanced research capabilities, and streamlined regulatory processes. The company aims for further research and market expansion, and will leverage the area's international openness to boost its global presence.

This strategic move aligns with Innovent's vision of becoming an internationally leading biopharmaceutical company. By accelerating product development and innovation, Innovent aims to help transform Hongqiao into a hub for biopharmaceutical talent, innovation, and international market access.